Home/Filings/4/0001415889-25-004754
4//SEC Filing

Troupin Barbara 4

Accession 0001415889-25-004754

CIK 0001746466other

Filed

Feb 18, 7:00 PM ET

Accepted

Feb 19, 7:30 PM ET

Size

8.1 KB

Accession

0001415889-25-004754

Insider Transaction Report

Form 4
Period: 2025-02-14
Transactions
  • Award

    Director Stock Option (right to buy)

    2025-02-14+40,00040,000 total
    Exercise: $0.79Exp: 2032-02-29Common Stock (40,000 underlying)
  • Disposition to Issuer

    Director Stock Option (right to buy)

    2025-02-1440,0000 total
    Exercise: $3.59Exp: 2032-02-29Common Stock (40,000 underlying)
Footnotes (2)
  • [F1]The option vests in 36 equal monthly installments following the grant date of March 1, 2022.
  • [F2]On August 7, 2023, the Board of Directors of the Company approved the repricing of certain options based on the closing price of the Company's common stock on August 14, 2023. The repricing of these options was subject to a holding period that lapsed on February 14, 2025. The repricing resulted in the impacted options having a lower exercise price of $0.785 per share, which is the closing price of the Company's common stock on the Nasdaq Capital Market on August 14, 2023. All of the other terms of the options remained unchanged.

Issuer

Equillium, Inc.

CIK 0001746466

Entity typeother

Related Parties

1
  • filerCIK 0001627886

Filing Metadata

Form type
4
Filed
Feb 18, 7:00 PM ET
Accepted
Feb 19, 7:30 PM ET
Size
8.1 KB